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Adenosine analogs, such as N6-cyclohexyladenosine (CHA) that are selective for A,-adenosine receptors, and analogs, such as S-N-ethylcarbox- 
amidoadenosine (NECA) that are active at both A, and 4 receptors, cause a profound depression of locomotor activity in mice via a central 
mechanism. The depression is effectively reversed by non-selective adenosine antagonists uch as theophylline. We report that 2-[(2-aminoethyl- 
amino)carbonylethylphenylethylamino]-S-~-ethylcarboxamidoadenosine (APEC), an amine derivative of the h-selective agonist, CGS21680, is 
a potent locomotor depressant in mice. The in vivo pharmacology is consistent with &-selectivity at a central site of action. Two parameters indica- 
tive of locomotor activity, horizontal activity and total distance travelled, were measured using a computerized activity monitor. From dose-respon- 
se curves it was found that APEC (ED,, 16 fig/kg) is more potent than CHA (ED,, 60 yg/kg) and less potent than NECA (ED,, 2 pg/kg). The 
locomotor depression by APEC was reversible by theophylline, but not by the A,-selective antagonists S-cyclopentyltheophylline (CPT) and 8-cyclo- 
pentyl-1,3-dipropyl-2-thioxanthine, orby the peripheral antagonists 8-p-sulfophenyltheophylline (&PST) and 1,3-dipropyl-Q-sulfophenylxanth- 
ine. The locomotor activity depression elicited by NECA and CHA was reversed by A,-selective antagonists. These results suggest hat the effects 
of APEC are due to stimulation of 4 adenosine receptors in the brain. 
Adenosine analog; Locomotor depression; Adenosine receptor 
1. INTRODUCTION 
Adenosine, as a neuromodulator, inhibits the firing 
of neurons and the release of neurotransmitters in the 
central nervous system [l]. In behavioral models, 
adenosine agonists, acting via a central mechanism, 
cause a dramatic depression of locomotor activity, 
which is effectively reversed by the non-selective 
adenosine antagonists, caffeine and theophylline [2]. 
This effect has been demonstrated in rodents using a 
number of potent adenosine analogs, including the 
non-selective agonist, N-ethylcarboxamidoadenosine 
(NECA), and the Ai selective agonists, N6-cyclohexyl- 
and N6-cyclopentyladenosine [3-51. The potencies in 
producing hypomobility, as measured by head dipping 
and locomotor assays, of a series of adenosine agonists 
were recently found to correlate to the potencies of the 
analogs at AZ receptors [a], suggesting that primarily 
A2 receptors are involved in these effects. The lack of 
a truly AZ-selective agonist has hampered these studies. 
Recently, several classes of AZ-selective adenosine 
agonists have been reported. N6-[2-(3,5dimethoxy- 
phenyl)-2-(2-methylphenyl)ethyl]adenosine [7] and 
2 - (carboxyethylphenylethylamino)adenosine-5 ’ - carbox- 
amide (CGS21680) [8,9] are AZ-selective in com- 
petitive binding experiments at central Ai- (measured in 
Correspondence address: 0. Nikodijevic, Laboratories of Chemistry 
and Bioorganic Chemistry, National Inst. of Diabetes, Digestive and 
Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, 
USA 
cortex) and AZ- (measured in striatum) adenosine 
receptors by factors of 32 and 140, respectively. 
CGS21680 was also shown to be Az-selective in the car- 
diovascular system [9]. CGS21680 contains a car- 
boxylic acid functionality, which is expected to limit its 
passage across the blood/brain barrier [9]. Using a 
functionalized congener approach, a series of long- 
chain derivatives of CGS21680 that retain A2 potency 
and selectivity and do not contain the carboxylic func- 
tionality, was synthesized [IO]. An amine derivative, 
2-[(2-aminoethyl-amino)carbonylethylphenylethylami- 
no]-5 ’ -carboxamidoadenosine (APEC; l), served as a 
synthetic intermediate for molecular probes for Az-ade- 
nosine receptors, including the first photo-affinity 
ligand, “‘I-PAPA-APEC [l 11. We report that APEC, 
which is 17-fold AZ-selective in vitro [lo], is a potent 
locomotor depressant in mice. The in vivo phar- 
macology is consistent with AZ-selectivity at a central 
site of action. 
2. MATERIALS AND METHODS 
2. I. Chemicals 
NECA, CHA, 8-PST, CPT, DPSPX and XAC were obtained from 
Research Biochemicals, Inc. (Natick, MA). 2-Thio-CPX [13] was the 
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generous gift of Professor W. Pfleiderer (Univ. of Konstanz, FRG 
and Dr J. Neumeyer, RBI). CGS 21680C (Na salt) was the generous 
gift of Dr A. Hutchison (CIBA-Geigy Corp.). APEC was synthesized 
as described [lo]. 
2.2. Animal studies 
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2.2.1. Subjects 
Adult male mice of the NIH (Swiss) strain weighing 25-30 g were 
housed in groups of 12 animals per cage with a light-dark cycle of 
12 : 12 h. The animals were given free access to standard pellet food 
and water and were habituated for 24 h in laboratory conditions 
prior to testing. Each animal was used only once in the activity 
monitor. 
2.2.2. Locomotor activity 
Individual animals were studied in a Digiscan activity monitor 
(Omnitech Electronics Inc., Columbus, OH) equipped with an IBM- 
compatible computer. Data was collected in the morning, for 3 con- 
secutive intervals of 10 min each and analyzed as a group for 30 min 
sampling period. Two non-equivalent parameters 1151 were analyzed: 
(i) horizontal activity, which represents the total number of beam in- 
terruptions in the horizontal direction; and (ii) total distance travell- 
ed, which indicates the distance in cm travelled by the animal. The 
tatter is dependent on the path taken. 
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2.2.3. Drug administration 
Fig. 1. Dose-response curves for locomotor depression in mice by the 
adenosine agonists, NECA (squares), APEC (triangles) and CHA 
(circles). For each analog, percent decrease compared to vehicle 
control is shown for horizontal activity (open symbols) and total 
All drugs were dissolved in a 1: 4 v/v mixture of Emulphor EL-620 
(GAF Chemicals Corp., Wayne, NJ) and phosphate-buffered saline 
and administered i.p. in a vol. of 5 ml/kg b. wt. Warming and 
sonication aided in dissolving the drugs. When appropriate, an 
adenosine antagonist was injected first followed by an agonist after 
10 min. Immediately after the final injection, the mouse was placed 
in the activity monitor cage, and data collection was begun after a 
delay of 10 min. Statistical analysis was performed using the Stu- 
dent’s f-test. Each value reported represents the mean f SE for 6-10 
animals, except for the control points (vehicle injected) for which 
n = 22. 
3. RESULTS 
The locomotor effects at different doses of APEC 
and the adenosine agonists NECA and CHA, ad- 
ministered intraperitonealiy in mice, were measured. 
The dose-response curves are given in fig. 1. APEC was 
found to have an EDso value for horizontal activity of 
14pg/kg b. wt. Thus, APEC is more potent than 
CHA (EDSO = 70pg/kg) and less potent than NECA 
(EDso = 2pg/kg). CGS21680 was also tested as a 
locomotor depressant at several doses. CGS21680 at a 
dose of 16 ,ug/kga was nearly inactive with 3 t 0.2% 
and 13 + 1% depression of horizontal activity (h.a.) 
and total distance travelled (t.d.), respectively. At a 
dose of 1 pmol/kg, CGS21680 caused decreases of 
64 f 4.5% (h.a.) and 62 f 5% (t.d.) in locomotor ac- 
tivity, and at 3 pmollkg the locomotor depression was 
94 i 9% (h.a.) and 96 + 20% (t.d.). 
depression by APEC. Similarly, the more potent 
1,3-dipropyl-8-Cp-sulfophenyl)xanthine (DPSPX) at 
5 mglkg did not antagonize APEC (fig.2). Since 8-PST 
and DPSPX are reIatively non-selective, a peripheral 
action at either AI or A2 subtypes is prectuded as the 
mechanism for the locomotor depression by APEC. 
Curiously, at high doses, these peripheral antagonists 
both elicited some locomotor depression. This depres- 
sion is particularly evident in the effect of 10 mg/kg 
&PST on total distance travelled (24 rt 2% decrease). 
At 5 mg/kg the depressant effect on total distance 
travelled was 6 + 0.5% and 12 it 1.8% for g-PST and 
The locomotor depressant activity of APEC was not 
reversed by the peripheral adenosine antagonist, 8-p- 
sulfophenyltheophylline (S-PST; fig.%). This is consis- 
tent with a central mechanism for the locomotor 
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a The dose equal to the average of EDsa values for APEC for 
horizontal activity and total distance (corresponds to 0.03 Bmol/kg 
APEC). 
Fig.2. The effects of the peripheral adenosine antagonists, g-PST and 
DPSPX, on locomotor depression induced by APEC (16rg/kg). 
Changes in horizontal activity (solid bars) and total distance travelled 
(hatched bars), relative to vehicle control, are shown. 
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DPSPX, respectively. The Al-selective antagonist, 
2-thioCPX (see below), depressed locomotor activity 
only at a dose of 10 mg/kg, with decreases of 23 + 3% 
(h.a.) and 28 + 3.6% (t.d.). The mechanisms underly- 
ing such depressant effects are unclear. At a dose of 
10 mg/kg 8-@-sulfophenyl)caffeine, which is struc- 
turally related to B-PST but inactive or weakly active, 
respectively, as an adenosine antagonist at At and AZ 
receptors [ 161, stimulated locomotor activity slightly by 
6 -t 0.2% (h.a.) and 12 t- 1.8% (t.d.). 
The Al-selective antagonist, %cyclopentyltheo- 
phylline (CPT), has been reported to antagonize the 
central depressant activities of adenosine agonists, such 
as Nd-cyclopentyladenosine [4]. Similarly, we found 
that CPT could reverse the depression by an EDso dose 
of CHA (fig.3), an agonist that is Al-selective by a fac- 
tor of 390 [ 121. The depression evoked by an EDso dose 
of NECA, an agonist that has marked activity at both 
adenosine receptor subtypes, was also completely 
reversed by this Al-selective antagonist (fig.4). 
However, the locomotor depression evoked by APEC 
was not reversible by a comparable dose of CPT (fig.4). 
This suggests that the depressant effect of APEC is due 
to stimulation of AZ adenosine receptors in the brain. 
The depressant effects of APEC were reversed by the 
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Fig.3. The effects of the Al-selective adenosine antagonist, CPT, on 
locomotor depression induced by CHA (60 pg/kg). Percent changes 
in total distance travelled (A) and horizontal activity (B), relative to 
vehicle control, are shown. 
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Fig.4. The effects of an Al-selective antagonist on locomotor 
depression induced by adenosine 5 ’ -carboxamide analogs. The 
percent change in locomotor activity, relative to vehicle control, 
induced by NECA (2 fig/kg) and APEC (16 pg/kg) at the EDso doses, 
in the presence (hatched bars) and absence (solid bars) of 10 mg/kg 
CPT, is shown. 
non-selective antagonist heophylline. At the EDso dose 
of APEC, 10 mg/kg theophylline restore the total 
distance travelled to 95 f 12% of control. 
In contrast to PST, DPSPX and 2-thio-CPX at high 
doses, CPT alone at 10 mg/kg was found to be a weak 
central stimulant (fig.3) causing increases of 41 f 8% 
and 24 + 7% for total distance travelled and horizontal 
activity, respectively. This finding is in contrast to a 
previous report [4] in which no stimulation by CPT (up 
to 30 mg/kg) was seen. To further study the effects of 
Al-selective adenosine antagonists on the locomotor 
depression by APEC, we searched for another centrally 
active Al-selective xanthine. The potent (Ki = 0.66 nM) 
and 480-fold Al-selective antagonist, S-cyclopentyl- 
1,3-dipropyl-2-thioxanthine (2-thio-CPX) [ 13,141, was 
shown to reverse the locomotor depression elicited by 
CHA (data not shown). At a dose of 5 mg/kg, 2-thio- 
CPX alone, unlike CPT, did not appreciably stimulate 
locomotor activity (increases of 1 + 0.1% in both h.a. 
and t.d.). Like CPT, this xanthine failed to antagonize 
the locomotor effects of APEC, further supporting the 
conclusion of in vivo A2 selectivity of APEC. A com- 
bination of 5 mg/kg 2-thio-CPX and the EDso dose of 
APEC depressed locomotor activity by 50 + 10% (h.a.) 
and 55 f 13% (t.d.). 
4. DISCUSSION 
The results show that APEC, previously determined 
to be AZ-selective in binding assays at rat brain 
adenosine receptors [lo], is a potent locomotor depres- 
sant in mice. The dose-response curves and the EDso 
values for the effects of adenosine agonists on two 
parameters indicative of locomotor activity (horizontal 
69 
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activity and total distance travelled; fig.1) show an 
order of potency of NECA > APEC > CHA. CHA 
(Ki5 = 10 nM) is also less potent than NECA and 
APEC (Ki = 10.3 and 5.73 nM, respectively) in com- 
petitive binding experiments at AZ adenosine receptors 
[10,12]. The locomotor effects of APEC were not 
reversed by the Al-selective adenosine antagonists, 
CPT and 2-thio-CPX. Both of these xanthines are cen- 
trally active antagonists and both reverse the locomotor 
depression elicited by the A1 agonist, CHA. Moreover, 
the effect of the non-selective antagonist, theophylline, 
and the inactivity of peripheral, non-selective an- 
tagonists, PST and DPSPX, in reversing locomotor 
depression elicited by APEC suggests central action at 
adenosine receptors. The lack of antagonism of APEC- 
elicited depression by the Ar-selective xanthines, CPT 
and 2-thio-CPX, strongly suggests that activation of A2 
receptors are involved in the behavioral depression. 
Prior studies have suggested that activation of either AI 
or AZ receptors can elicit dramatic depressant effects 
[2-61. APEC now provides an important tool for in- 
vestigation of the role of central AZ receptors, just as 
the Al-selective agonists, CHA and CPA, provide tools 
for investigation of the role of central A1 receptors. 
CGS21680, the structural precursor of APEC, has 
been evaluated as a potentially therapeutic, hypotensive 
agent 191. The charged carboxylate group is predicted 
to tend to restrict the action of this potent and highly 
selective A2 adenosine agonist (Ki = 14 nM) to the 
periphery [8]. It is possible that the reason for the 
behavioral inactivity of CGS21680 at a low dose, at 
which APEC is active, is due to diminished passage 
across the blood/brain barrier. At higher doses, 
CGS21680 acts as a locomotor activity depressant, but 
less potent than CHA. The aliphatic amino group of 
APEC is predominantly but not completely charged at 
physiological pH, which obviously does not prevent its 
entry into the CNS. 
Yet to be resolved is why NECA is much more potent 
than APEC despite similar affinity at AZ-receptors. In 
addition to pharmacokinetic factors, there remains the 
possibility that dual activation of AI and Aa receptors 
by NECA is acting synergistically on locomotor depres- 
sion. The blockade by CPT of NECA-elicited 
behavioral depression [4] suggests a key role for Ar 
receptors, yet other data [3] suggests that A2 receptors 
are involved. Preliminary results (unpublished) suggest 
that the effects of APEC and CHA are more than ad- 
ditive, supporting possible synergistic interactions of 
Ar and A2 receptors in eliciting behavioral depression. 
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